Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 87 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Recurrence 16 Burkitt Lymphoma 13 Neoplasms 10 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8 Leukemia, Biphenotypic, Acute 7 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6 Lung Neoplasms 6 Immunoglobulin Light-chain Amyloidosis 6 Neoplasms, Plasma Cell 5 Hodgkin Disease 5 Smoldering Multiple Myeloma 4 Leukemia 4 Carcinoma, Non-Small-Cell Lung 4 Waldenstrom Macroglobulinemia 3 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Nausea 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma 3 Brain Neoplasms 3 Renal Insufficiency 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell 2 Lymphoma, B-Cell 2 Leukemia, Plasma Cell 2

Interventions

Radiosurgery 3 Androgen Antagonists 3 pembrolizumab 1 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 cabazitaxel 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostate Cancer Metastatic × Dexamethasone × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡